mTOR pathway: A current, up-to-date mini-review

Oncology Letters

Volumn 8, Issue 6, 2014, Pages 2367-2370

  Zarogoulidis, Paul ^a   Lampaki, Sofia ^a   Francis Turner, J ^b   Huang, Haidong ^c   Kakolyris, Stylianos ^d   Syrigos, Konstantinos ^e   Zarogoulidis, Konstantinos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Western Regional Medical Center   (United States)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^e UNIVERSITY OF ATHENS   (Greece)

Author keywords

Lung cancer; mTOR; Targeted therapy

Indexed keywords

BINDING PROTEIN; DEP DOMAIN CONTAINING MAMMALIAN TARGET OF RAPAMYCIN INTERACTING PROTEIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; INITIATION FACTOR 4E BINDING PROTEIN 1; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM; PROTEIN KINASE B; PROTEIN S6; RIDAFOROLIMUS; S6 KINASE; SCATTER FACTOR RECEPTOR; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; CANCER PROGNOSIS; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG CARCINOGENESIS; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN SYNTHESIS; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; SMALL CELL LUNG CANCER; TISSUE MICROARRAY;

EID: 84908037236     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2608     Document Type: Review

References (54)

1. Liu P, Cheng H, Roberts TM and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627-644, 2009.
2. Myers AP and Cantley LC: Targeting a common collaborator in cancer development. Sci Transl Med 2: 48ps45, 2010.
3. McCubrey JA, Steelman LS, Franklin RA, et al: Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. Adv Enzyme Regul 47: 64-103, 2007.
4. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
5. Bhaskar PT and Hay N: The two TORCs and Akt. Dev Cell 12: 487-502, 2007.
6. Lee DF and Hung MC: All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle 6: 3011-3014, 2007.
7. Pirker R, Pereira JR, Szczesna A, von Pawel J, et al; FLEX study team: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373: 1525-1531, 2009.
8. Tortora G, Ciardiello F and Gasparini G: Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol 5: 521-530, 2008.
9. Gridelli C, Maione P and Rossi A: The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 13: 139-147, 2008.
10. Tokunaga C, Yoshino K and Yonezawa K: mTOR integrates amino acid-and energy-sensing pathways. Biochem Biophys Res Commun 313: 443-446, 2004.
11. Beevers CS, Li F, Liu L and Huang S: Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer 119: 757-764, 2006.
12. Huang S and Houghton PJ: Mechanisms of resistance to rapamycins. Drug Resist Updat 4: 378-391, 2001.
13. Huang S, Bjornsti M and Houghton P: Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2: 222-232, 2003.
14. Lazaridis G, Lambaki S, Karayannopoulou G, et al: Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer. Strahlenther Onkol 190: 636-638, 640-645.
15. Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell 124: 471-484, 2006.
16. Betz C and Hall MN: Where is mTOR and what is it doing there? J Cell Biol 203: 563-574, 2013.
17. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P and Sabatini DM: mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175, 2002.
18. Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, Tempst P and Sabatini DM: GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 11: 895-904, 2003.
19. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A and Chen J: Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 294: 1942-1945, 2001.
20. Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA and Sabatini DM: mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16: 1865-1870, 2006.
21. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P and Sabatini DM: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302, 2004.
22. Betz C, Stracka D, Prescianotto-Baschong C, Frieden M, Demaurex N and Hall MN: Feature Article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology. Proc Natl Acad Sci USA 110: 12526-12534, 2013.
23. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101, 2005.
24. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, Gaffney PR, Reese CB, McCormick F, Tempst P, Coadwell J and Hawkins PT: Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 279: 710-714, 1998.
25. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM and Baur JA: Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335: 1638-1643, 2012.
26. Tang JM, He QY, Guo RX and Chang XJ: Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51: 181-191, 2006.
27. Dowling RJ, Topisirovic I, Fonseca BD and Sonenberg N: Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta 1804: 433-439, 2010.
28. Dunlop EA and Tee AR: Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cell Signal 21: 827-835, 2009.
29. Wislez M, Spencer ML, Izzo JG, et al: Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 65: 3226-3235, 2005.
30. Balsara BR, Pei J, Mitsuuchi Y, Page R, et al: Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25: 2053-2059, 2004.
31. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008.
32. Sarosi V, Losonczy G, Francovszky E, Tolnay E, Torok S, Galffy G, Hegedus B, Dome B and Ostoros G: Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE). Lung Cancer 86: 54-58, 2014.
33. Gridelli C, de Marinis F, Cappuzzo F, et al: Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer 15: 173-181, 2014.
34. Laurent-Puig P, Pekin D, Normand C, Kotsopoulos S, Nizard P, Perez Toralla K, Rowell R, Olson J, Srinivasan P, Le Corre D, et al: Clinical relevance of KRAS-mutated sub-clones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res: Sep 23, 2014 (Epub ahead of print).
35. Choughule A, Sharma R, Trivedi V, Thavamani A, Noronha V, Joshi A, Desai S, Chandrani P, Sundaram P, Utture S, et al: Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer. Br J Cancer: Aug 12, 2014 (Epub ahead of print).
36. Conde E, Angulo B, Tang M, et al: Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res 12: 710-717, 2006.
37. Legrier ME, Yang CP, Yan HG, et al: Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res 67: 11300-11308, 2007.
38. Buck E, Eyzaguirre A, Brown E, et al: Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5: 2676-2684, 2006.
39. Glaysher S, Bolton LM, Johnson P, Torrance C and Cree IA: Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model. BMC Res Notes 7: 397, 2014.
40. Jänne PA, Cohen RB, Laird AD, et al: Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. J Thorac Oncol 9: 316-323, 2014.
41. Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, et al: Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol 16: 567-578, 2014.
42. Wang Q, Wei F, Li C, Lv G, Wang G, Liu T, Bellail AC and Hao C: Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma. PLoS One 8: e73175, 2013.
43. Bauman JE, Arias-Pulido H, Lee SJ, Fekrazad MH, Ozawa H, Fertig E, Howard J, Bishop J, Wang H, Olson GT, et al: A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol 49: 461-467, 2013.
44. Papadimitrakopoulou VA, Soria JC, Jappe A, Jehl V, Klimovsky J and Johnson BE: Everolimus and erlotinib as second-or third-line therapy in patients with advanced non-small-cell lung cancer. J Thorac Oncol 7: 1594-1601, 2012.
45. Bago-Horvath Z, Sieghart W, Grusch M, Lackner A, Hayden H, Pirker C, Komina O, Węsierska-Gądek J, Haitel A, Filipits M, et al: Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway. Neuroendocrinology 96: 228-237, 2012.
46. Matar P, Rojo F, Cassia R, et al: Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 10: 6487-6501, 2004.
47. O'Donnell A, Faivre S, Burris HA III, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26: 1588-1595, 2008.
48. Besse B, Leighl N, Bennouna J, et al: Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. Ann Oncol 25: 409-415, 2014.
49. Owonikoko TK, Stoller RG, Petro D, et al: Phase II study of RAD001 (Everolimus) in previously treated small cell lung cancer (SCLC). J Clin Oncol 26 (Suppl 15): 19017, 2008.
50. Pandya KJ, Dahlberg S, Hidalgo M, et al; Eastern Cooperative Oncology Group (E1500): A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2: 1036-1041, 2007.
51. Mita MM, Mita AC, Chu QS, et al: Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 26: 361-367, 2008.
52. Milton DT, Riely GJ, Azzoli CG, et al: Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 110: 599-605, 2007.
53. Riely GJ, Kris MG, Zhao B, et al: Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13: 5150-5155, 2007.
54. Papadimitrakopoulou V, Blumenschein GR Jr, Leighl NB, et al: A phase 1/2 study investigating the combination of RAD0001 (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): phase 1 results. J Clin Oncol 26 (Suppl 15): 8051, 2008.